Patents by Inventor Patrick Baumhof
Patrick Baumhof has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131142Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: ApplicationFiled: January 4, 2024Publication date: April 25, 2024Applicants: CureVac SE, Sanofi PasteurInventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
-
Publication number: 20240101608Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.Type: ApplicationFiled: December 4, 2023Publication date: March 28, 2024Applicant: CureVac SEInventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
-
Patent number: 11931406Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: GrantFiled: December 12, 2018Date of Patent: March 19, 2024Assignees: CureVac SE, Sanofi PasteurInventors: Patrick Baumhof, Wolfgang Grosse, Edith Jasny, Thomas Kramps, Daniel Voss, Julia Dannenmaier, Valérie Lecouturier, Yves Girerd-Chambaz
-
Publication number: 20230338579Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: ApplicationFiled: September 7, 2022Publication date: October 26, 2023Applicant: CureVac SEInventors: Mariola FOTIN-MLECZEK, Aleksandra KOWALCZYK, Regina HEIDENREICH, Patrick BAUMHOF, Jochen PROBST, Karl-Josef KALLEN
-
Publication number: 20230302146Abstract: A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of the lipidoid in the composition is preferably low, relative to the cationic peptide or polymer.Type: ApplicationFiled: October 20, 2022Publication date: September 28, 2023Applicant: CureVac SEInventors: Patrick BAUMHOF, Carolin THIELE, Joanna REJMAN
-
Publication number: 20230285594Abstract: The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g.Type: ApplicationFiled: November 3, 2022Publication date: September 14, 2023Applicant: CureVac SEInventors: Patrick BAUMHOF, Söhnke VOSS, Thomas KRAMPS, Karl-Josef KALLEN
-
Publication number: 20230272052Abstract: The invention relates inter alia to a nucleic acid composition for the expression of at least two antibodies, preferably a mixture of assembled antibodies in a cell or subject, wherein at least one coding sequence of the nucleic acid composition encodes at least one antibody chain assembly promoter. Further, the invention relates to a nucleic acid sequence set for expression of at least one assembled antibody and to a combination of different nucleic acid sequence sets. Additionally, first and second medical uses, methods of treating or preventing diseases, disorders or conditions, and methods for the production of antibody mixtures are provided.Type: ApplicationFiled: July 30, 2021Publication date: August 31, 2023Applicant: CureVac SEInventors: Hans Wolfgang GROßE, Patrick BAUMHOF
-
Patent number: 11690910Abstract: The present invention is directed to a pharmaceutical composition including (e.g. for use as an adjuvant) a polymeric carrier cargo complex, comprising as a carrier a polymeric carrier formed by disulfide-crosslinked cationic components; and as a cargo at least one nucleic acid molecule, and at least one antigen that is selected from an antigen from a pathogen associated with infectious disease; an antigen associated with allergy or allergic disease; an antigen associated with autoimmune disease; or an antigen associated with a cancer or tumour disease, or in each case a fragment, variant and/or derivative of said antigen. The pharmaceutical composition allows for efficient induction of an adaptive immune response directed against said antigen. The present invention furthermore provides kits, as well as the use of the pharmaceutical composition or the kit as a vaccine, particularly in the treatment of infectious diseases, allergies, autoimmune diseases and tumour or cancer diseases.Type: GrantFiled: August 29, 2019Date of Patent: July 4, 2023Assignee: CureVac SEInventors: Patrick Baumhof, Thomas Kramps, Söhnke Voss, Karl-Josef Kallen, Mariola Fotin-Mleczek
-
Publication number: 20230190578Abstract: The present invention relates to nanoparticles comprising nucleic acids coated with a (biodegradable) polymer for reversible immobilization and/or controlled release of the nucleic acid comprising nanoparticles. Furthermore, the present invention is directed to medical or diagnostic devices, particularly stents and implants coated by a (biodegradable) polymer with the nucleic acid comprising nanoparticles for reversible immobilization and/or controlled release. Furthermore, the present invention is directed to the use of these nanoparticles coated with a (biodegradable) polymer and to the use of medical devices and implants coated by the (biodegradable) polymer with these nucleic acid comprising nanoparticles in the prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of restenosis, calicification, foreign body reaction, or inflammation.Type: ApplicationFiled: October 26, 2022Publication date: June 22, 2023Applicant: CureVac SEInventors: Patrick BAUMHOF, Hans-Peter WENDEL, Andrea NOLTE, Tobias WALKER
-
Publication number: 20230090515Abstract: The application relates to cationic lipids and to compositions comprising said cationic lipids useful for the delivery of nucleic acids into living cells.Type: ApplicationFiled: December 18, 2020Publication date: March 23, 2023Applicant: CureVac AGInventors: Gemma NAVARRO, Patrick BAUMHOF
-
Patent number: 11478552Abstract: A composition for the delivery of a nucleic acid compound is provided which comprises a cationic peptide or polymer and a lipidoid compound. The nucleic acid compound may be any chemically modified or unmodified DNA or RNA. The amount of the lipidoid in the composition is preferably low, relative to the cationic peptide or polymer.Type: GrantFiled: June 9, 2017Date of Patent: October 25, 2022Assignee: CureVac AGInventors: Patrick Baumhof, Carolin Thiele, Joanna Rejman
-
Publication number: 20220133908Abstract: The invention relates inter alia to compositions comprising coding RNA for use in treatment of an ophthalmic disease, disorder or condition, wherein said composition is administered into the suprachoroidal space of a subject in need of treatment. Additionally, methods of treating or preventing ophthalmic diseases, disorders or conditions are provided.Type: ApplicationFiled: February 7, 2020Publication date: May 5, 2022Applicant: CureVac AGInventors: Joanna REJMAN, Patrick BAUMHOF
-
Publication number: 20210251898Abstract: The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.Type: ApplicationFiled: January 6, 2021Publication date: August 19, 2021Applicants: CureVac AG, Acuitas Therapeutics Inc.Inventors: Patrick BAUMHOF, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Michael J. HOPE, Edith JASNY, Sandra LAZZARO, Paulo Jia Ching LIN, Johannes LUTZ, Barbara MUI, Benjamin PETSCH, Susanne RAUCH, Kim Ellen SCHMIDT, Ying TAM
-
Publication number: 20210069315Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.Type: ApplicationFiled: December 12, 2018Publication date: March 11, 2021Inventors: Patrick BAUMHOF, Wolfgang GROSSE, Edith JASNY, Thomas KRAMPS, Daniel VOSS, Julia DANNENMAIER, Valérie LECOUTURIER, Yves GIRERD-CHAMBAZ
-
Publication number: 20210060175Abstract: The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.Type: ApplicationFiled: November 5, 2020Publication date: March 4, 2021Applicant: CureVac AGInventors: Mariola FOTIN-MLECZEK, Patrick BAUMHOF
-
Patent number: 10918740Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: GrantFiled: July 19, 2018Date of Patent: February 16, 2021Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Aleksandra Kowalczyk, Regina Heidenreich, Patrick Baumhof, Jochen Probst, Karl-Josef Kallen
-
Publication number: 20200399322Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g.Type: ApplicationFiled: September 9, 2020Publication date: December 24, 2020Applicant: CureVac AGInventors: Patrick BAUMHOF, Susanne RAUCH, Aleksandra KOWALCZYK, Johannes LUTZ, Edith JASNY, Benjamin PETSCH, Andreas THESS, Thomas SCHLAKE, Mariola FOTIN-MLECZEK, Regina HEIDENREICH, Sandra LAZZARO, Fatma FUNKNER, Wolfgang GROSSE
-
Patent number: 10869935Abstract: The present invention relates to RNA containing compositions for use in the treatment or prophylaxis of tumor and/or cancer diseases, to a pharmaceutical composition, to a kit and to uses of the RNA containing compositions for the treatment or prophylaxis of tumor and/or cancer diseases.Type: GrantFiled: February 4, 2019Date of Patent: December 22, 2020Assignee: CureVac AGInventors: Mariola Fotin-Mleczek, Aleksandra Kowalczyk, Regina Heidenreich, Patrick Baumhof, Jochen Probst, Karl-Josef Kallen
-
Publication number: 20200338215Abstract: The present invention is directed to an inventive polymeric carrier molecule according to generic formula (I) and variations thereof, which allows for efficient transfection of nucleic acids into cells in vivo and in vitro, a polymeric carrier cargo complex formed by a nucleic acid and the inventive polymeric carrier molecule, but also to methods of preparation of this inventive polymeric carrier molecule and of the inventive polymeric carrier cargo complex. The present invention also provides methods of application and use of this inventive polymeric carrier molecule and the inventive polymeric carrier cargo complex as a medicament, for the treatment of various diseases, and in the preparation of a pharmaceutical composition for the treatment of such diseases.Type: ApplicationFiled: July 15, 2020Publication date: October 29, 2020Applicant: CureVac AGInventors: Patrick BAUMHOF, Thomas SCHLAKE
-
Patent number: 10799602Abstract: The invention relates to an RNA comprising at least one open reading frame (ORF) and comprising at least one modification, which increases the expression of the encoded peptide or protein. Furthermore, the invention relates to the medical use of such a modified RNA administered to a subject by jet injection. The invention relates further to a pharmaceutical composition and to a kit of parts comprising said modified RNA for administration by jet injection, preferably for use in the field of gene therapy and/or genetic vaccination. Additionally, the invention relates to a method for enhancing the (localized) expression of RNA-encoded peptides or proteins in the dermis or muscle (of a mammal) comprising administering the modified RNA by jet injection. And finally, the invention relates to a method of treatment comprising administering the modified RNA by jet injection to a subject in need thereof.Type: GrantFiled: April 1, 2019Date of Patent: October 13, 2020Assignee: CureVac AGInventor: Patrick Baumhof